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From the beginning of 2020, the governments and the health systems around
the world are tackling infections and fatalities caused by the novel severe acute
respiratory syndrome coronavirus (SARS-CoV-2) resulting in the coronavirus disease
2019 (COVID-19). This virus pandemic has turned more complicated as individuals with
co-morbidities like diabetes, cardiovascular conditions and obesity are at a high risk
of acquiring infection and suffering from a more severe course of disease. Prolonged
viral infection and obesity are independently known to lower the immune response and
a combination can thus result in a “cytokine storm” and a substantial weakening of
the immune system. With the rise in obesity cases globally, the chances that obese
individuals will acquire infection and need hospitalization are heightened. In this review, we
discuss why obesity, a low-grade chronic inflammation, contributes toward the increased
severity in COVID-19 patients. We suggest that increased inflammation, activation
of renin-angiotensin-aldosterone system, elevated adipokines and higher ectopic fat
may be the factors contributing to the disease severity, in particular deteriorating the
cardiovascular and lung function, in obese individuals. We look at the many lessons learnt
from the 2009 H1N1 influenza A pandemic and relate it to the very little but fast incoming
information that is available from the SARS-CoV-2 infected individuals with overweight
and obesity.
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INTRODUCTION
In the last 50 years, obesity has gradually shaped into a pandemic. Obesity (body mass index (BMI),
≥30 kg /m2) is a combination of genetic, behavioral and environmental variables, and the number
of affected individuals has doubled in more than 70 countries. It is not just restricted to developed
nations; it is also present in low to middle-income countries (1). With 100 million obese children
and 670 million obese adults worldwide, the challenges of tackling obesity involving health, social
and economic issues are paramount, and no country is able to reverse the obesity epidemic so far
(2, 3).
Many obese individuals may not show any adverse health condition at the onset but if not
controlled, checked or reversed, obesity could contribute and develop other co-morbidities such
as cardiovascular diseases, diabetes and cancers (3, 4). Many respiratory issues like obstructive
sleep apnea, asthma and chronic obstructive pulmonary disease (COPD) have been correlated with
obesity (5). Moreover, the incidences of acute respiratory distress syndrome (ARDS) is increased
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in parallel with body mass (6). Besides causing non-
communicable conditions, in recent years it is suggested that
excess adiposity is an ideal set-up for acquiring and spreading
of communicable diseases, in particular viral infections (7).
Moreover, obesity is also linked to urinary tract, periodontitis,
nosocomial and surgical infections (8).
The hallmarks of obesity include increase in hypertrophy and
hyperplasia of adipocytes, ectopic fat deposition and adipose
inflammation (9, 10). Besides adipocytes and preadipocytes, the
other cell types present in adipose tissue comprise of endothelial
and resident immune cells (11). During the progression of
obesity, the dynamics and the functionality of the adipocytes
change leading to altered levels of secreted adipokines and a rise
in pro-inflammatory immune cells (12).
Undernutrition, which is still prevalent in many developing
countries, was suspected to be the responsible factor for the
spread of infection (13). However, observations during the H1N1
influenza virus pandemic indicated that overnutrition along with
sedentary lifestyle (factors that mediate obesity) increase the
risk of infection. A study by the World Health Organization
(WHO), with H1N1 infection involving 70,000 individuals from
19 countries provide evidence that obesity, particularly morbid
obesity (BMI > 40), is a risk factor for severe disease (14).
Emerging strong evidence suggests that excess adiposity and
chronic inflammation increase the susceptibility to infection
(15). With elevated levels of pro-inflammatory cytokines, the
immune system is dysregulated making it difficult to combat
infection (8). A correlation between obesity and infections is
suggested by humans and rodent studies (16, 17) and reflects
the reduced ability of immune cells from obese individuals
to fight viral infection. However, the molecular mechanisms
for this correlation are elusive and might even vary between
viral infections.
Obesity is an expensive condition costing the society and the
health system billions of dollars in treatment (18). With the
increased frequency of viral infections, the cost of obesity gets
even higher. At this time, when the world is facing a pandemic
with the novel corona virus (SARS-CoV-2), it is important to
use our current understanding on the connection between viral
infection and obesity. In the light of the lessons, we learned from
the H1N1 influenza A virus pandemic in an obese setting, this
review discusses why obese individuals are at risk during this
SARS-CoV-2 pandemic.
OBESITY AND IMMUNE SYSTEM
In healthy adipose tissue, adipocytes and the resident
leukocytes maintain a balanced homeostatic state and a steady
communication either through messenger cytokines or through
cell-cell contact (19). Both the innate and adaptive immune cells
reside in the adipose tissue to maintain an anti-inflammatory
environment and obesity disturbs this situation (20, 21). Indeed,
in obese adipose tissue an increase in macrophage accumulation
along with a rise in TNF-α and IL-6 inflammatory molecules
has been reported (22, 23). Obesity also results in an increase
in ectopic fat accumulation in the bone marrow, which is the
site where immune cells develop (24). Thus, the interplay of
adipocytes and immune cells is altered in obesity compromising
immune cell function and giving rise to inflammation.
Not just resident immune cells, the circulating cells are also
affected by obesity. In this regard, the total leukocyte and
monocyte count in the blood was shown to be increased in obese
individuals as compared to lean counterparts (25). Moreover, the
circulating peripheral blood mononuclear cells (PBMCs) secrete
higher levels of TNF-α and lower levels of the anti-inflammatory
IL-10 in obese individuals establishing a permanent “low-grade
inflammatory state” (26). Toll like receptors (TLRs) play a
crucial role in innate immune system and their activation in
PBMCs from obese individuals indicate an impaired ability to
express anti-viral type 1 interferons (IFNs), namely IFN-α and
IFN-β (27). The circulating PBMCs differentiate into tissue-
resident macrophages, which represent a large proportion of
immune cell population in the adipose tissue. It is suggested
that with an increase in hypertrophied adipocytes and rise in
adipose tissue inflammation, the macrophages switch to a pro-
inflammatory M1 type (28). Other immune cells, such as those
that mediate the adaptive immune response are also affected
by obesity (29). The rise in T cell subpopulations such as Th1
and Th17 cause a pro-inflammatory response in obese adipose
tissue (30–32). The pro-inflammatory state in obesity is further
enhanced by the depletion of regulatory T cell (Tregs), which
is associated with infiltration of immune cells and a rise in
inflammation (33). Thus, in obesity the proportion of pro-
inflammatory immune cells are increased and together with
inflammation from hypertrophied adipocytes they create a robust
localized and systemic inflammation.
Adipose tissue was traditionally considered a long-term
energy storage organ, but it is now appreciated that it
orchestrates metabolic functions by the secretion of adipokines
such as adiponectin and leptin (34). Moreover, adipokines have
immunomodulatory roles and obesity disturbs this function (35–
37). Plasma levels of leptin are highly correlated with BMI in both
rodents and humans (38, 39) and influence T cell proliferation
and Th1/ Th17-dependent cytokine secretion (40). Leptin affects
fat and glucose metabolism and is linked to elevated free fatty
acids and glucose levels in obesity and diabetes (38). Such high
levels of glucose suppress the anti-viral type 1 IFN production in
PBMCs (41, 42) and increase the reactive oxygen species in T cells
(43). Elevated free fatty acids activate TLRs, induce inflammatory
cytokines in circulating monocytes and enhance inflammation in
T cells (44–47).
Thus, excess adiposity mediated by the changes in the levels
of cytokines, adipokines and metabolites derails the immune
response and shifts the balance to a pro-inflammatory state,
which most likely favors and promotes infection.
INFLUENZA VIRUS INFECTION IN
OBESITY
Globally 250,000 to 500,000 individuals die of influenza virus
and 3 to 5 million individuals, both children and adults, are
severely affected annually by this highly contagious virus (48).
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Cold-weather months and low relative humidity due to room
heating promotes the spread of this virus, which is known to
cause severe respiratory tract infection along with rapid onset of
high fever, cough, and possible headache, sore throat, body aches,
nausea and/ or vomiting (49).
The genetic material of this virus is segmented RNA, which
is surrounded by a host lipid envelop and is decorated on
the surface by hemagglutinin and neuraminidase viral peptides,
which help in attachment to the host cell (50). Influenza A, B,
C, and D are the four strains, and A and B are the common
strains that infect humans. Most human cases are caused by
H1N1 and H3N2 influenza A virus strains (51) and to escape the
host immunity, the virus goes through antigenic shift and drift
causing seasonal influenza epidemics (50).
One hundred years back, the influenza virus triggered the
1918 “Spanish Flu” pandemic, which caused an extraordinary
mortality of 50–100 million deaths (52). However, in those days
obesity was not wide spread in the society, rather undernutrition
was an issue. Since then other pandemics have taken place, which
were caused by zoonotic transfer of the virus from animals to
humans, but none of those created such an adverse impact as the
Spanish Flu in 1918.
After the 2009 pandemic of influenza A (H1N1) virus, an
in-depth analysis of the data revealed that obesity was an
independent risk factor for increased morbidity and mortality
(53). Obesity is often associated with reduced lung volume,
abnormalities in respiratory muscle function and gas exchange
compounded by sleep apnea and chronic inflammation (5, 54),
and this restricted lung function seems highly conducive for
the influenza virus infection and thereby injury in the lungs.
Recently, increase in BMI positively correlated with adiposity in
airway wall, wall thickness and inflammation causing asthma-
related death (55). Influenza virus pathogenicity is not just
restricted to lungs (56); it also worsens the cardiovascular
function (57).
Using rodent models of obesity, many studies have been
performed with influenza virus to understand why obesity is
a risk factor for infection. High-fat diet-induced obese (DIO)
mice infected with influenza virus develop greater lung damage
and inflammation, and exhibit a higher mortality rate (58).
Increased leptin levels in DIO mice caused severe lung injury
and anti-leptin antibody improved the survival of H1N1 infected
obese mice (59). The genetic models of obesity such as the
leptin deficient ob/ob mice and leptin receptor-deficient obese
db/db mice have increased susceptibility to H1N1 virus infection
(60). Increased leptin levels in obesity may promote infection
by lowering anti-viral type 1 IFN through the activation of
suppressor of cytokine signaling-3 (SOCS-3) expression (42, 61).
Indeed disruption of SOCS-3 expression provides protection
against influenza A virus infection (62).
The role of antiviral IFNs has also been investigated as it
is the key to immunity, and suppressed IFN production could
be the link for increased infection in obesity (42). In mice, the
reduced IFN response in obese condition was shown to create
an ideal microenvironment permitting diversity and emergence
of virulent strains and treatment with recombinant IFN reduced
the viral diversity (63). Most of the studies on the effect of obesity
during infection investigated the lungs, which is the primary site
for influenza virus infection. The natural killer (NK) cells assist
in eliminating infected cells, and infection in obese mice had
diminished NK cell cytotoxicity, lower expression of IFN α/β and
delayed expression of pro-inflammatory cytokines like IL-6 and
TNFα in the lungs (17), indicating lower immune response. DIO
mice had reduced influenza specific CD8+memory T cells post-
infection along with a reduction in leptin receptors in the lungs,
suggesting possibility of lung injury (64). Obesity also affected the
presence of monocytes, lymphocytes and antigen presentation
by dendritic cells during infection leading to impairment of
immune response in the lungs (65). However, in contrast to the
lungs, adipose tissue have a higher infiltration of inflammatory
cells, and increased levels of TNFα, MCP-1, and IL-6 (66),
which are known to cause complications like insulin resistant
and also dysfunctional adipose tissue. Besides inflammatory
mediators, metabolic profiling of serum, adipose tissue, liver,
lungs, urine and feces from obese mice infected with influenza
virus showed differential increase in specific metabolites such as
certain lipids, ascorbate, glucose, 3-hydroxybutyrate, all known
to affect the T cell population (67), thus lowering the adaptive
immune response.
In humans, the extent of adiposity determines the severity of
disease post-infection. The influenza viral RNA was detected in
aerosol and there was a positive association with viral aerosol load
(indicating shedding) and BMI (68). Higher BMIwas shown to be
an added risk factor for hospitalization and during the influenza
months of the year, the incidences of hospitalization with obese
individuals increased (69, 70). Moreover, obese individuals had
a longer hospital stay. Indeed, the data suggests that obesity
slows the recovery since it delays the clearance of the influenza
virus load and prolongs the shedding duration causing long-
term transmission (71). Obese individuals infected with H1N1
virus had a two-fold higher chance to end up in Intensive
Care Unit (ICU) (72). A multicenter study with 144 ICUs in
Spain revealed that obesity was associated with higher ICU
resource consumption and hospitalization in H1N1 infected
individuals (73). Among patients admitted to ICU due to H1N1
infection, obese and morbidly obese patients were more likely to
develop pneumonitis compared to non-obese patients (74). With
underlying co-morbidities like obesity and diabetes even younger
patients over the age of 20 years had higher hospitalization and
mortality (53, 75, 76). Thus, the influenza pandemic data shows
that obesity is a risk regardless of age and possible other co-
morbidities such as hypertension and diabetes could enhance the
severity of the disease.
INFLUENZA VIRUS VACCINATION IN
OBESITY
Vaccination is still the best way to prevent the risk of developing
infections. Obesity, however, interferes with the protection by
vaccination against infectious diseases (7) and indeed obese
individuals were reported to show a greater decline in influenza-
specific antibody titers at 1 year after vaccination (77). Moreover,
vaccinated obese adults had twice the risk of developing influenza
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despite a good antibody titer in response to the vaccine (78).
PBMCs challenged ex vivo with vaccine virus strain showed that
obese individuals had decreased CD8+ T cell numbers along
with a decline in influenza antibody titers and lower protection
to vaccination (77). In a further study by the same group,
PBMCs from overweight and obese individuals when stimulated
ex vivo with H1N1 virus showed a defect in CD4+ and CD8+ T
cell activation despite intact dendritic cell functions, suggesting
that both overweight and obesity negatively impact the immune
function (79).
The above studies with influenza virus show that excess
body fat elevates inflammation, weakens the immune response
particularly in the lungs, hampers vaccination and creates an
ideal environment for influenza viral infection and spreading.
IS OBESITY A RISK FACTOR FOR
SARS-COV-2?
Coronaviruses (CoVs) are a family of enveloped RNA viruses
that infect mammals and birds. The last two decades saw
the emergence of novel coronaviruses that triggered human
fatalities. Firstly, in 2002/2003 there was the outbreak of SARS-
CoV and then in 2012, the World saw an outbreak of Middle
East respiratory syndrome coronavirus (MERS-CoV). Both these
viruses originated from animals and infected humans (80).
Though these viruses did not spread efficiently from human to
human, both SARS and MERS had a high fatality rate of 9.5
and 34.4%, respectively (81). Comorbidities were reported to
exist in MERS infected individuals and in one such study obesity
was associated with 17% of the MERS infected hospitalized
patients (82). The 2002 SARS-CoV infection lowered anti-viral
IFNα/β, upregulated TNF receptor, IL-8 and hypoxia related
genes (83). Obesity also lowers the IFNs activity and increases
hypoxia in adipocytes leading to a heightened inflammation
(42, 84). Hence, the combination of the viral infection and
obesity probably creates an ideal platform that favors a pro-
viral inflammatory “cytokine storm” by lowering the anti-viral
immune response.
The 2019 novel coronavirus, referred to as SARS-CoV-2, is
closer to SARS as it also binds to human angiotensin-converting
enzyme 2 (ACE2). ACE2, which is also referred to as ACE2
receptor acts as the entry point for the coronavirus to infect a
wide range of human cells. The viral spike protein S present
as transmembrane protein in the viral envelope has a strong
affinity for human ACE2 receptor. ACE2 is expressed in a
wide variety of human tissues with different expression levels
including the small intestine, testis, kidneys, heart, thyroid,
lungs, brain and the adipose tissue (85–88). ACE2 is known
to generate vasodilator angiotensin-(1-7) from vasoconstrictor
angiotensin II, and expression of ACE2 in adipocytes is known
to protect against obesity-mediated hypertension (89). ACE2
induces an anti-obesity effect by stimulating brown adipocytes
and through browning of white adipose tissue (90). Moreover,
activator of ACE2 is reported to reduce adiposity (91). Thus,
it is highly probable that the beneficial effects of adipose ACE2
are lost after the binding with SARS-CoV-2. Loss and/ or
reduction in ACE2 activity means increase in Ang II levels and
indeed Covid-19 patients show increased levels of plasma Ang-II,
cardiovascular complications and a linear association with lung
injury (92).
Recent studies suggest that COVID-19 patients with obesity
are at a greater risk for hospitalization. Obesity was suggested
as an independent risk factor for SARS-CoV-2 infection and
the proportion of patients in France who required invasive
mechanical ventilation increased with BMI (93). In Spain, obesity
was the strongest comorbidity among patients admitted to
ICU (94). In a retrospective analysis of COVID-19 patients
admitted to a hospital in Wuhan, China, 88% of non-
survivor patients had a BMI >25 kg/m2 (95). A report from
Intensive Care National Audit and Research Center (ICNARC,
UK) from 19 June, 2020 show that of the 9,272 COVID-
19 patients admitted in critical care units 39.3% were obese
& 35% were overweight (https://www.icnarc.org/Our-Audit/
Audits/Cmp/Reports). In USA, which is witnessing an explosion
of SARS-CoV-2 infection, 40% of the adult population is obese.
In an Editors Speak Out column Ryan et al., suggest that, in
USA, obese individuals are at risk of infection and obesity
could be an independent risk factor for COVID-19 (96). Data
of 5,700 COVID-19 patients from the New York City area
with median age of 63 years show that many patients had
comorbidities such as obesity (41.7%), hypertension (56.6%)
and diabetes (33.8%) (97). A letter communicated by Lighter
J et al., on the COVID-19 patient data from a New York
City hospital report that in patients younger than 60 years,
obesity is a risk factor for hospital admission (98). The authors
indicate that of the 3,615 patients admitted in the hospital 38%
were with a BMI of ≥30 kg/m2 and that obesity increases
the likelihood of admission in critical care unit by 2 times as
compared to those with lower BMI in the same age group.
Similar data was reported in young obese individuals with
H1N1 infection (53). With all the data pouring in, it is still
unclear why SARS-CoV-2 infection deteriorates the health and
increases the hospitalization of COVID-19 overweight and
obese patients.
The driving features of SARS-CoV-2 are reduced levels
of anti-viral IFNs along with high levels of chemokine and
cytokines like IL-6 (99). Even though inflammation of the
lung is the primary symptom in COVID-19 patients, the
expression of ACE2 in lungs is very moderate (88). Even
with moderate ACE2 expression, it may be enough to drive
the lung inflammation. Li et al., found no difference in the
expression levels of ACE2 in the lungs of healthy individuals
and those with chronic respiratory disease, suggesting that in
both groups SARS-CoV-2 could infect the lungs (100). Hence, the
additional underlying conditions such as obesity could contribute
to worsen the lung function. Obesity is related with chronic
obstructive pulmonary disease (COPD) and ACE2 expression
is significantly increased in COPD than non-COPD subjects
(101). Besides causing acute respiratory distress syndrome
(ARDS) and pneumonia, SARS-CoV-2 also causes cardiovascular
complications (102).
Until now, most of the studies on SARS-CoV-2 have focused
on the lungs even though other organs such as adipose tissue and
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FIGURE 1 | Excess adiposity provides an ideal setting to promote viral infection. We propose that obesity and its associated conditions elevate the cytokines,
adipokines and RAAS and increase ectopic fat accumulation. When infection sets in, in this case with SARS-COV-2, through ACE2 receptor on the adipose tissue,
the lungs, the heart and the blood vessels, the virus enters, mediates a cytokine storm and creates an imbalance in AngII/ACE-2 levels, elevates leptin levels and
lowers anti-viral molecules like IFNs. Moreover, adipose tissue a might serve as a reservoir for viral persistence, which could be the possible source of continuous viral
shedding and systemic inflammation. The combination of all the factors deteriorates lungs and the cardiovascular system, weakens the immune response, and
promotes viral shedding. Yellow circle indicate adipocytes, red marks indicate inflammatory cells, upwards and downwards arrows indicates upregulation or
downregulation of molecules and/ or effect.
heart have higher expression of ACE2 (88). Whether a cross talk
exists, by which infection in adipose tissue affects the lung and
heart function is a matter of investigation. Based on the present
findings, we suggest the following possible factors through which
excess adiposity in the presence of SARS-CoV-2 deteriorate
health, in particular the lungs and cardiovascular function.
Inflammation
Expression of inflammatory molecules (IL-6, TNFα) and C-
reactive protein are increased in overweight and obesity (103,
104) and increased inflammation is shown to deteriorate the lung
and the cardiovascular function. High levels of IL-6 is associated
with lung lesions after SARS infection (105) and increased
levels of circulating IL-6 is connected with systolic blood
pressure in hypertensive subjects by increasing the expression of
angiotensinogen and angiotensin II receptor (106). Data from
COVID-19 patients show that a cytokine storm exist in severe
patients and highly elevated IL-6 levels in the serum contributes
to the cytokine release syndrome (107, 108), which could
probably reduce the immune response in lungs by inhibiting the
ability of dendritic cells to activate T cells (109).
Renin-Angiotensin-Aldosterone System
(RAAS)
The ACE2-Ang II balance is altered by both obesity and
by SARS-CoV-2 infection. Activation of RAAS results in
higher blood pressure and elevated levels of Ang II induces
endothelial dysfunction (110). Moreover, SARS-CoV-2 viral
elements have been reported within endothelial cells along with
an accumulation of inflammatory cells (111), which could further
worsen the cardiovascular system. In the lungs, downregulation
of ACE2 receptors is shown to cause immune-cell infiltration
and expression of inflammatory cytokines leading to lung edema
and acute lung failure, which appear to be mediated by Ang
II (112).
Adipokines
Leptin levels are increased in obesity and elevated leptin
levels deteriorate lung and cardiovascular function (59, 113).
It is reported that COVID-19 patients with high BMI have
significantly higher levels of serum leptin (doi: https://doi.org/10.
1101/2020.04.30.20086108).
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Ectopic Fat
An increase in ectopic fat, in obesity, may worsen the function
of the organ that is in close proximity to the adipose tissue.
For example: the epicardial adipose tissue (EAT) which is in
close proximity with the myocardium could be a possible source
for myocarditis and indeed myocarditis is reported in COVID-
19 patients (114). Fat embolism in lungs through the action of
the released lipid droplets from necrotic adipose tissue could be
another way by which obesity affects lung function upon viral
infection (115).
Even though there are several similarities between influenza and
SARS-CoV-2 virus and both these viruses worsen the lung and
cardiovascular function in obese setting, some differences also
exist. Both viruses utilize different entry points to bind and enter
the cells. Even though there is a report which suggests that
influenza virus utilizes ACE2 to induce acute lung damage (116)
however for SARS-CoV-2 infection, ACE2 is the main route to
infection. It is highly important for clinicians and health workers
to distinguish between the two types of infections, which have
almost the same readouts. It is suggested that COVID-19 patients
have a higher median age, higher proportions male subjects, a
history of cardiovascular diseases as compared to H1N1 patients
(117). The case fatality risk (CFR) suggest that COVID-19 ismore
severe than H1N1 infected hospitalized individuals (118).
Even though the information coming out on SARS-CoV-2 is
very rapid, some open questions remains.
Some Important Open Questions
1. Does SARS-CoV-2 infect the adipose tissue and enhance
the inflammation?
2. Do COVID-19 obese individuals have a longer virus shedding
duration and therefore need longer isolation period?
3. If SARS-CoV-2 reduces memory CD8+ T cells in obesity, then
how effective a vaccine will be for obese individuals?
4. Will countries with less obese individuals per million of
population, have a lower morbidity and mortality rate
to SARS-CoV-2?
CONCLUSION
Based on the studies, we suggest that obesity favors viral
infection (both influenza and COVID-19). At this stage of
the COVID-19 pandemic, it is evident that obesity and
infection together build up a cytokine storm that determines
the severity of the disease. Moreover, increased inflammation
in particular elevated IL-6 levels, activation of RAAS, rise
in Ang II levels, higher leptin and increased ectopic fat
favor COVID-19 disease progression and severity, and thus
worsen the lung and cardiovascular function (Figure 1).
The lower levels of anti-viral IFNs and weakened immune
response in COVID-19 patients make the fight against this
infection more difficult and the effect of a potential vaccine
questionable in obese individual. Therefore, overweight and
obese individuals should be informed that they belong to a risk
group and should avoid the risk of SARS-CoV-2 infection by
any means.
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